Parameter
| Biomarker | CD3 | Full name | Cluster of differentiation 3 | Molecular Type | Protein (T cell marker) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Treatment targets, diagnostics (phenotype monitoring when relapse occurs) |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tumor tissue (conventional pathological detection techniques such as immunohistochemistry) | ||
| Pathobiological Mechanisms | As a T cell marker, the loss or reduction of its expression may influence disease progression. | ||||
| Clinical Availability Status | Validation phase: Relevant studies have explored its association with prognosis, requiring larger-scale data validation | ||||
| Notes and Dynamics | It is a potential key variable for the prognostic evaluation of pediatric ALCL, and its expression status can assist in optimizing treatment strategies and stratifying recurrence risk. | ||||